Article tools
Author information

Research Article

Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

L I Brasoveanu, E Fonsatti, A Visintin, M Pavlovic, I Cattarossi, F Colizzi, A Gasparollo, S Coral, V Horejsi, M Altomonte and M Maio

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Published September 1, 1997

Protectin (CD59), a glycosylphosphatidylinositol-anchored cell membrane glycoprotein, is differentially expressed on melanocytic cells and represents the main restriction factor of C-mediated lysis of melanoma cells. In this study, we report that CD59-positive melanoma cells constitutively release a soluble form of CD59 (sCD59), and that its levels directly correlate (r = 0.926; P < 0.05) with the amount of membrane-bound CD59. SDS-PAGE analysis showed that the molecular components of sCD59 are similar to those of cellular CD59 expressed by melanoma cells. Melanoma-released sCD59 is anchor positive since it inserts into cell membranes of homologous cells that transiently increase their expression of CD59. Moreover, sCD59 is functional: it blocks the binding of the anti-CD59 mAb YTH53.1 to melanoma cells and reverses its effects on C-mediated lysis. In fact, preincubation of mAb YTH53.1 with scalar doses of conditioned media of CD59-positive but not of CD59-negative melanoma cells reduced significantly (P < 0.05), and in a dose-dependent fashion, the enhancement of C-mediated lysis of anti-GD3-sensitized melanoma cells induced by the masking of cellular CD59 by mAb YTH53.1. Altogether, these data demonstrate that CD59-positive human melanoma cells release a soluble form of CD59 that is structurally similar to cellular CD59, retains its anchoring ability, is functional, and may impair the effectiveness of clinical approaches to humoral immunotherapy for human melanoma.

Articles that cite this article:

Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement
Sandra Coral, Ester Fonsatti, Luca Sigalotti, Chiara De nardo, Alberto Visintin, Gianpaolo Nardi, Francesca Colizzi, Mario P. Colombo, Gaetano Romano, Maresa Altomonte
J Cell Physiol 185(3):317. doi:10.1002/1097-4652(200012)185:3&lt;317::AID-JCP1&gt;3.0.CO;2-L [CrossRef]

K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement
Katrin Jurianz, Stefanie Ziegler, Natalie Donin, Yoram Reiter, Zvi Fishelson, Michael Kirschfink
Int J Cancer 93(6):848. doi:10.1002/ijc.1406 [CrossRef]

Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer
Neil K. Rushmere, Janice M. Knowlden, Julia M.W. Gee, Maureen E. Harper, John F. Robertson, B. Paul Morgan, Robert I. Nicholson
Int J Cancer 108(6):930. doi:10.1002/ijc.11606 [CrossRef]

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid
N. Donin, K. Jurianz, L. Ziporen, S. Schultz, M. Kirschfink, Z. Fishelson
Clin Exp Immunol 131(2):254. doi:10.1046/j.1365-2249.2003.02066.x [CrossRef]

Expression of complement regulator proteins in primary and metastatic malignant melanoma
Michael Weichenthal, Ute Siemann, Karsten Neuber, Eckard W. Breitbart
J Cutan Pathol 26(5):217. doi:10.1111/j.1600-0560.1999.tb01833.x [CrossRef]